It is consistent with that dexmedetomidine alleviates LPS-induced AKI by inhibiting the activation of the NLRP3 inflammasomes and IL-18 and IL-1β levels via inhibiting the TLR4/NOX4/NF-κB pathway (Yao et al. 2019). This evidence concerns the gene NFKB1 and acute kidney injury.